Acquisition

#Acquisition #Investment #Supply chain

Ilya Pharma acquires Nordic Bioanalysis to bolster supply chain 

Immunotherapy company Ilya Pharma has acquired Nordic Bioanalysis in a move to strengthen its supply chain and help develop its pipeline of skin and mucosal immunotherapy drug candidates.  Nordic Bioanalysis was founded in 2019 and serves as an international expert in bioanalytical development and validation for pharmaceuticals,… Read More

#News

#Acquisition #Business #Immuno-oncology #Pharma

GSK to acquire Sierra Oncology in £1.5bn deal 

GlaxoSmithKline (GSK) is to acquire biopharmaceutical company Sierra Oncology in a deal worth £1.5 billion, the company has announced.   Sierra Oncology  Sierra Oncology is a late-stage company focused on targeted therapies for the treatment of rare forms of cancer. The company’s lead asset, momelotinib, is being… Read More

#Business & Investment #News

#Acquisition #Collaboration #Oncology #T-Cells #Therapeutics

Takeover plan looks to develop T cell engager therapies 

Tokyo-based Takeda Pharmaceutical has optioned to acquire Adaptate Biotherapeutics, a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells.   The acquisition   Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programmes. Adaptate’s γδ T cell engagers are… Read More

#News